Med Business World

Your source for healthcare business


Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent® (dupilumab) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12…

Dupixent® (dupilumab) is now approved in India for the treatment of adults with moderate-to-severe atopic dermatitis

Sanofi Healthcare India Pvt. Ltd. has announced a milestone in dermatological treatment with the approval of Dupixent® (dupilumab), a novel biologic medicine for adults with moderate-to-severe atopic dermatitis. Unlike traditional treatments that broadly suppress the immune system, Dupixent® specifically targets…